Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here